EPM speaks to Dan Dobry, director, head of Commercial Development, Small Molecule Drug Product at Lonza to learn about how to ensure good bioavailability across compounds and which therapy areas are benefitting from targeted drug delivery.
Break through
Q: How do you ensure good bioavailability across such a differing range of compounds in pharma?
A: The key to improving bioavailability across a range of compounds with differing physical-chemical properties is to strategically choose the best technology for each compound. At Lonza, we use a science-based approach to determine the mechanism of poor bioavailability along with bulk-sparing methodologies that allow each technology to be evaluated in vitro. This approach is based on learnings gained from screening thousands of molecules and progressing hundreds to clinical development or commercial production.